Healthy subjects
Conditions
Sponsors
HUMA R&D CORP
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Healthy adult who aged 20 years or older and younger than 65 years 2.Subjects with feces frequency 2-5 times / week
Exclusion criteria
Exclusion criteria: 1.Subjects diagnosed with constipated by a physician. 2.Subjects with chronic conditions such as brain disease, malignancies, gastrointestinal, immunological, and respiratory diseases, diabetes mellitus, liver disease (hepatitis), and kidney, heart, thyroid, adrenal, and metabolic diseases, and subjects who currently have or previously had serious manifestations of these conditions. 3.Subjects who routinely use from using medicines or quasi-drugs that affect bowel control, such as bowel regulators, laxatives and laxatives. 4.Subjects who habitually consume yogurt, natural cheese, kefir, lactic acid bacteria beverages, supplements or syrups containing bifidobacteria, lactobacilli, oligosaccharides, etc., or Foods with Function Claims or Foods for Specified Health Uses containing oligosaccharides as a functional substance. 5.Subjects who are unable to stop using medicines, quasi-drugs, foods or supplements that affect bowel regulators during the study period. 6.Subjects receiving medication or outpatient treatment for a disease. 7.Subjects who are at risk of having allergic reactions to drugs or foods. 8.Subjects with current or previous history of drug dependence or alcohol dependence. 9.Heavy users of alcohol (the mean consumption of pure alcohol is 60 g/day or more). 10.Subjects receiving exercise or diet therapy under the supervision of a physician. 11.Subjects who have extremely irregular life rhythms due to night work, shift work, etc. 12.Subjects whose eating, sleeping, and other habits are extremely irregular. 13.Subjects who are having a very unbalanced diet. 14.Smoker 15.Subjects who are currently pregnant or lactating, may become pregnant during the study period. 16.Subjects who participated in another clinical study/research within 3 months before the date of informed consent or who plan to participate in another clinical study/research during the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fecal frequency | — |
Secondary
| Measure | Time frame |
|---|---|
| (Secondary outcomes) Fecal characteristics, Gastrointestinal symptoms | — |
Countries
Japan
Contacts
Public ContactHiroyuki Miyazawa
HUMA R&D CORP Clinical Development Department
Outcome results
None listed